FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971657493> ?p ?o ?g. }

• W1971657493 endingPage "e11778" @default.
• W1971657493 startingPage "e11778" @default.
• W1971657493 abstract "The emergence of drug resistant typhoid fever is a major public health problem, especially in Asia. An oral single dose typhoid vaccine would have major advantages. M01ZH09 is a live oral single dose candidate typhoid vaccine containing Salmonella enterica serovar Typhi (Ty2 aroC(-)ssaV(-)) ZH9 with two independently attenuating deletions. Studies in healthy adults demonstrated immunogenicity and an acceptable safety profile.We conducted a randomised placebo controlled, single-blind trial to evaluate the safety and immunogenicity of M01ZH09 in healthy Vietnamese children aged 5 to 14 years.Subjects were randomly assigned to receive either a nominal dose of 5x10(9) CFU of M01ZH09 or placebo and were followed up for 28 days. The primary safety outcome was the proportion of subjects with any adverse event attributed to M01ZH09. The primary immunogenicity endpoint was the proportion of subjects who showed a positive immune response to M01ZH09 in the Salmonella Typhi lipopolysaccharide (LPS) specific serum IgA and IgG ELISA.One hundred and fifty-one children were enrolled, 101 subjects received M01ZH09 and 50 subjects received placebo. An intention to treat analysis was conducted. There were no serious adverse events and no bacteraemias. In the M01ZH09 group, 26 (26%; 95% CI, 18-5%) of 101 subjects experienced adverse events compared to 11 (22%; 95% CI, 12-36%) of 50 subjects in the placebo group (odds ratio (OR) [95%CI] = 1.23 [0.550-2.747]; p = 0.691). Faecal shedding of S. Typhi (Ty2 aroC(-)ssaV(-)) ZH9 was detected in 51 (51%; 95% CI, 41-61%) of 100 M01ZH09 subjects. No shedding was detected beyond day 3. A positive immune response, defined as 70% increase (1.7 fold change) in LPS specific serum IgG (day 14 or 28) and/or 50% increase (1.5 fold change) in LPS specific serum IgA (day 7 or 14) from baseline was detected in 98 (97%; 95% CI, 92-99%) of 101 M01ZH09 recipients and 8 (16%; 95% CI, 7-29%) of 50 placebo recipients. Twenty-eight (100%; 95% CI, 88-100%) of 28 vaccine recipients who were evaluated in the LPS specific IgA ELISPOT assay showed a positive response compared to none of the 14 placebo recipients tested.This was the first phase II trial of a novel oral candidate typhoid vaccine in children in an endemic country. M01ZH09 had an appropriate safety profile and was immunogenic in children.Controlled-trials.com ISRCTN91111837." @default.
• W1971657493 created "2016-06-24" @default.
• W1971657493 creator A5005427167 @default.
• W1971657493 creator A5006346036 @default.
• W1971657493 creator A5009114319 @default.
• W1971657493 creator A5012502070 @default.
• W1971657493 creator A5014182020 @default.
• W1971657493 creator A5014485456 @default.
• W1971657493 creator A5014500238 @default.
• W1971657493 creator A5017234930 @default.
• W1971657493 creator A5022386747 @default.
• W1971657493 creator A5032122956 @default.
• W1971657493 creator A5039131208 @default.
• W1971657493 creator A5039475324 @default.
• W1971657493 creator A5041415916 @default.
• W1971657493 creator A5055295874 @default.
• W1971657493 creator A5056799272 @default.
• W1971657493 creator A5065887025 @default.
• W1971657493 creator A5067650157 @default.
• W1971657493 creator A5069436379 @default.
• W1971657493 creator A5076197621 @default.
• W1971657493 creator A5078360219 @default.
• W1971657493 creator A5080395456 @default.
• W1971657493 creator A5080952496 @default.
• W1971657493 creator A5083342797 @default.
• W1971657493 creator A5084899853 @default.
• W1971657493 creator A5085096483 @default.
• W1971657493 creator A5085198062 @default.
• W1971657493 creator A5085926025 @default.
• W1971657493 date "2010-07-26" @default.
• W1971657493 modified "2023-10-11" @default.
• W1971657493 title "A Randomised Trial Evaluating the Safety and Immunogenicity of the Novel Single Oral Dose Typhoid Vaccine M01ZH09 in Healthy Vietnamese Children" @default.
• W1971657493 cites W1994232345 @default.
• W1971657493 cites W2012518985 @default.
• W1971657493 cites W2025454977 @default.
• W1971657493 cites W2051558015 @default.
• W1971657493 cites W2054839242 @default.
• W1971657493 cites W2091768490 @default.
• W1971657493 cites W2097448744 @default.
• W1971657493 cites W2133204402 @default.
• W1971657493 cites W2136369541 @default.
• W1971657493 cites W2147278081 @default.
• W1971657493 cites W2151222379 @default.
• W1971657493 cites W2165249729 @default.
• W1971657493 cites W2165663498 @default.
• W1971657493 cites W2167659135 @default.
• W1971657493 doi "https://doi.org/10.1371/journal.pone.0011778" @default.
• W1971657493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2909895" @default.
• W1971657493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20668668" @default.
• W1971657493 hasPublicationYear "2010" @default.
• W1971657493 type Work @default.
• W1971657493 sameAs 1971657493 @default.
• W1971657493 citedByCount "41" @default.
• W1971657493 countsByYear W19716574932012 @default.
• W1971657493 countsByYear W19716574932013 @default.
• W1971657493 countsByYear W19716574932014 @default.
• W1971657493 countsByYear W19716574932015 @default.
• W1971657493 countsByYear W19716574932016 @default.
• W1971657493 countsByYear W19716574932018 @default.
• W1971657493 countsByYear W19716574932020 @default.
• W1971657493 countsByYear W19716574932021 @default.
• W1971657493 countsByYear W19716574932023 @default.
• W1971657493 crossrefType "journal-article" @default.
• W1971657493 hasAuthorship W1971657493A5005427167 @default.
• W1971657493 hasAuthorship W1971657493A5006346036 @default.
• W1971657493 hasAuthorship W1971657493A5009114319 @default.
• W1971657493 hasAuthorship W1971657493A5012502070 @default.
• W1971657493 hasAuthorship W1971657493A5014182020 @default.
• W1971657493 hasAuthorship W1971657493A5014485456 @default.
• W1971657493 hasAuthorship W1971657493A5014500238 @default.
• W1971657493 hasAuthorship W1971657493A5017234930 @default.
• W1971657493 hasAuthorship W1971657493A5022386747 @default.
• W1971657493 hasAuthorship W1971657493A5032122956 @default.
• W1971657493 hasAuthorship W1971657493A5039131208 @default.
• W1971657493 hasAuthorship W1971657493A5039475324 @default.
• W1971657493 hasAuthorship W1971657493A5041415916 @default.
• W1971657493 hasAuthorship W1971657493A5055295874 @default.
• W1971657493 hasAuthorship W1971657493A5056799272 @default.
• W1971657493 hasAuthorship W1971657493A5065887025 @default.
• W1971657493 hasAuthorship W1971657493A5067650157 @default.
• W1971657493 hasAuthorship W1971657493A5069436379 @default.
• W1971657493 hasAuthorship W1971657493A5076197621 @default.
• W1971657493 hasAuthorship W1971657493A5078360219 @default.
• W1971657493 hasAuthorship W1971657493A5080395456 @default.
• W1971657493 hasAuthorship W1971657493A5080952496 @default.
• W1971657493 hasAuthorship W1971657493A5083342797 @default.
• W1971657493 hasAuthorship W1971657493A5084899853 @default.
• W1971657493 hasAuthorship W1971657493A5085096483 @default.
• W1971657493 hasAuthorship W1971657493A5085198062 @default.
• W1971657493 hasAuthorship W1971657493A5085926025 @default.
• W1971657493 hasBestOaLocation W19716574931 @default.
• W1971657493 hasConcept C104317684 @default.
• W1971657493 hasConcept C126322002 @default.
• W1971657493 hasConcept C142724271 @default.
• W1971657493 hasConcept C159047783 @default.
• W1971657493 hasConcept C159654299 @default.
• W1971657493 hasConcept C197934379 @default.
• W1971657493 hasConcept C203014093 @default.

• next